Clinical Trial Update: Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV/TB co-infected patients; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Tuberculosis

Drugs mentioned

• EFAVIRENZ (efavirenz)

Snippet

Sponsor: Shanghai Public Health Clinical Center | Conditions: HIV Infections, Tuberculosis | Phase 3 | Status: UNKNOWN